Intrepid Investment Bankers, a leading middle-market investment bank and the advisory arm of MUFG, a global financial group, announced today that it served as the exclusive financial advisor to Analyte Health, a digital health platform offering direct-to-consumer diagnostic and treatment services, on its sale to Brightstar Capital Partners, a private equity firm focused on partnering with exceptional founders, families, entrepreneurs, and management teams to build industry-leading companies.
Empowering a New Generation of Consumer Driven Telehealth
Analyte Health operates a portfolio of innovative digital healthcare platforms. Together, these platforms provide millions of patients with fast, affordable, and confidential access to lab testing, telemedicine, and treatment services—empowering individuals to take control of their health. Analyte has rapidly grown to be one of the leading consumer-facing telehealth platforms through a powerful model delivering high quality health insights and access to high quality clinical care coupled with unmatched convenience and access.
“We’ve spent the past 15 years building a platform that makes healthcare more accessible, affordable, and patient-centered,” said Fiyyaz Pirani, Founder and CEO of Analyte Health. “Brightstar’s investment marks a pivotal moment in our journey. Their operational expertise and long-term vision will help us scale our impact, expand our offerings, and continue to innovate in digital health. Intrepid did an amazing job presenting our unique business to investors given their knowledge of our space. They delivered at every stage and were an invaluable resource to help us secure an outstanding partner.”
Michael Singer, Partner at Brightstar commented, “Analyte Health is a category leader in DTC diagnostics and virtual care. We believe the company’s strong brand portfolio, scalable technology infrastructure, and commitment to patient experience make it a standout in the healthcare space well positioned to address a seismic shift in consumer demand. We’re excited to partner with Fiyyaz and his team to further expand Analyte’s offering and support its rapid growth.”
Why This Deal Matters
Adam Abramowitz, Managing Director and Co-Head of Healthcare & Life Sciences at Intrepid, commented, “Analyte Health has built a truly differentiated platform that sits at the intersection of diagnostics, telehealth, and consumer empowerment. Consumers are increasingly taking control of their healthcare journeys and not relying solely on traditional channels. Analyte’s platforms are perfectly positioned to address these megatrends by providing high-quality healthcare in a convenient and accessible format.”
Kyle Berkman, Director at Intrepid, added, “This partnership transaction helps accelerate Analyte’s development and provides it with enhanced resources to launch more innovative consumer healthcare solutions.”